Nicholas A Pavlidis

Summary

Affiliation: University of Ioannina
Country: Greece

Publications

  1. ncbi Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
    Vasilis Karavasilis
    Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 5:25. 2005
  2. ncbi Oncology for medical students: a European School of Oncology contribution to undergraduate cancer education
    N Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, 451 10 Ioannina, Greece
    Cancer Treat Rev 33:419-26. 2007
  3. ncbi The pregnant mother with breast cancer: diagnostic and therapeutic management
    Nicholas Pavlidis
    Department of Medical Oncology, Medical School, University Hospital of Ioannina, 45110 Ioannina, Hellas, Greece
    Cancer Treat Rev 31:439-47. 2005
  4. ncbi Coexistence of pregnancy and malignancy
    Nicholas A Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece
    Oncologist 7:279-87. 2002
  5. ncbi Diagnostic and therapeutic management of cancer of an unknown primary
    N Pavlidis
    University of Ioannina Hospital, Department of Medical Oncology, 451 10, Ioannina, Greece
    Eur J Cancer 39:1990-2005. 2003
  6. ncbi Carcinoma of unknown primary (CUP)
    Nicholas Pavlidis
    School of Medicine, Department of Medical Oncology, University of Ioannina, P O Box 1186, 451 10 Ioannina, Greece
    Crit Rev Oncol Hematol 69:271-8. 2009
  7. ncbi Cancer of unknown primary (CUP)
    Nicholas Pavlidis
    School of Medicine, Department of Medical Oncology, University of Ioannina, Greece
    Crit Rev Oncol Hematol 54:243-50. 2005
  8. ncbi Forty years experience of treating cancer of unknown primary
    Nicholas Pavlidis
    Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina, Greece
    Acta Oncol 46:592-601. 2007
  9. ncbi Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
    N Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, Greece
    Cancer Chemother Pharmacol 46:167-71. 2000
  10. ncbi Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression
    E Ioachim
    Department of Pathology, Medical School, University of Ioannina, 45110 Ioannina, Greece
    Eur J Cancer 38:2362-70. 2002

Collaborators

Detail Information

Publications55

  1. ncbi Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
    Vasilis Karavasilis
    Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 5:25. 2005
    ..We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets...
  2. ncbi Oncology for medical students: a European School of Oncology contribution to undergraduate cancer education
    N Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, 451 10 Ioannina, Greece
    Cancer Treat Rev 33:419-26. 2007
    ....
  3. ncbi The pregnant mother with breast cancer: diagnostic and therapeutic management
    Nicholas Pavlidis
    Department of Medical Oncology, Medical School, University Hospital of Ioannina, 45110 Ioannina, Hellas, Greece
    Cancer Treat Rev 31:439-47. 2005
    ..Several recommendations are also provided...
  4. ncbi Coexistence of pregnancy and malignancy
    Nicholas A Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece
    Oncologist 7:279-87. 2002
    ....
  5. ncbi Diagnostic and therapeutic management of cancer of an unknown primary
    N Pavlidis
    University of Ioannina Hospital, Department of Medical Oncology, 451 10, Ioannina, Greece
    Eur J Cancer 39:1990-2005. 2003
    ..Empirical chemotherapy benefits some of the patients who do not fit into any favourable sub-set, and should be considered in patients with a good performance status...
  6. ncbi Carcinoma of unknown primary (CUP)
    Nicholas Pavlidis
    School of Medicine, Department of Medical Oncology, University of Ioannina, P O Box 1186, 451 10 Ioannina, Greece
    Crit Rev Oncol Hematol 69:271-8. 2009
    ..Patients who belong to the non-favourable sub-sets have a worse prognosis...
  7. ncbi Cancer of unknown primary (CUP)
    Nicholas Pavlidis
    School of Medicine, Department of Medical Oncology, University of Ioannina, Greece
    Crit Rev Oncol Hematol 54:243-50. 2005
    ..Patients who belong to the non-favourable subsets have a worse prognosis...
  8. ncbi Forty years experience of treating cancer of unknown primary
    Nicholas Pavlidis
    Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina, Greece
    Acta Oncol 46:592-601. 2007
    ..This review article provides both a historical outline of CUP treatment as well as a helpful therapeutic guide to every oncologist who treats CUP patients...
  9. ncbi Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
    N Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, Greece
    Cancer Chemother Pharmacol 46:167-71. 2000
    ..In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed...
  10. ncbi Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression
    E Ioachim
    Department of Pathology, Medical School, University of Ioannina, 45110 Ioannina, Greece
    Eur J Cancer 38:2362-70. 2002
    ..In addition, overexpression of stromal TN and FN seems to have negative prognostic value in breast cancer patients...
  11. ncbi Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma
    E Tsanou
    Department of Pathology, Medical School, University of Ioannina, Ioannina, Greece
    Histol Histopathol 19:807-13. 2004
    ..In addition, MnSOD content varies according to the degree of differentiation of breast carcinoma...
  12. ncbi Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Med Oncol 23:147-60. 2006
    ..Paclitaxel coupled with carboplatin provides an alternative therapeutic option for anthracycline-exposed patients and warrants further clinical research in the direction of anthracycline-free management of metastatic breast cancer...
  13. ncbi Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components
    E Tsanou
    Dept of Pathology, Medical School, University of Ioannina, Ioannina, Greece
    J Exp Clin Cancer Res 23:641-50. 2004
    ..0067). The results of the present study show the implication of this protein in the remodeling of breast cancer tissue, through the interaction with other extracellular matrix components, probably influences the tumour progression...
  14. ncbi Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group
    E Briasoulis
    Medical Oncology Department, School of Medicine, University of Ioannina, 451 10, Ioannina, Greece
    Eur J Cancer 39:2334-40. 2003
    ..Haematological toxicity is particularly mild, but regular monitoring of renal function is recommended...
  15. ncbi Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer
    A Bamias
    Oncology Dept, Ioannina University Hospital, Ioannina, Greece
    J Chemother 15:275-81. 2003
    ..It may represent an attractive option in patients at high risk for developing specific irinotecan toxicity...
  16. ncbi Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors
    N Zagorianakou
    Department of Pathology, Medical School, University of Ioannina, Ioannina, Greece
    Histol Histopathol 21:341-7. 2006
    ..MT constitutes a marker that characterizes aggressiveness and a high malignant potential in ovarian epithelial tumors. In diagnostic problems MT may help distinguish between benign, borderline and malignant tumors...
  17. ncbi Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support
    E Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Respiration 67:680-3. 2000
    ..Corticosteroids can provide maximum benefit if started early upon diagnosis coupled with withdrawal of the causative drugs...
  18. ncbi Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP
    Nicholas Pavlidis
    Department of Medical Oncology, Ioannina University Hospital, 45500 Ioannina, Greece
    Clin Transl Oncol 11:340-8. 2009
    ..Recently introduced molecular profiling platforms may provide biological classification to a primary tissue of origin as well as insights into the pathophysiology of this clinical entity...
  19. ncbi Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
    G Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Macedonia, Greece
    Ann Oncol 17:1560-7. 2006
    ..In the present randomized phase III trial we compared two new combinations containing new drugs with proven activity in phase II studies with patients with HNC...
  20. ncbi Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy
    G Pentheroudakis
    Department of Medical Oncology, Medical School, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Cancer Chemother Pharmacol 60:733-9. 2007
    ..In this phase I study, we investigated an alternative, dose-intense continuous regimen...
  21. ncbi Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
    E Briasoulis
    Ioannina University Hospital, Ioannina, Greece
    Cancer Chemother Pharmacol 62:277-84. 2008
    ..We evaluated the irinotecan-oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas...
  22. ncbi Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes
    G Pentheroudakis
    Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
    Chemotherapy 51:154-61. 2005
    ..However, substantial myelosuppression undermines its applicability in the palliative setting, stressing the need for less toxic regimens...
  23. ncbi Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma
    V Karavasilis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Int J Gynecol Cancer 16:241-6. 2006
    ..36 months, P= 0.1). Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas. The findings of this study may offer support for considering VEGF-targeted therapeutics in ovarian cancer treatment research...
  24. ncbi Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors
    E Briasoulis
    Department of Medical Oncology, University of Ioannina, Ioannina, Greece
    Ann Oncol 15:1566-73. 2004
    ....
  25. ncbi G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
    E Briasoulis
    Department of Medical Oncology, University of Ioannina, Ioannina, Greece
    Cancer 91:909-17. 2001
    ..Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients...
  26. ncbi Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer
    E Andreopoulou
    Department of Medical Oncology, University of Ioannina, Greece
    Anticancer Res 22:1903-8. 2002
    ..Initial tumor volume has prognostic significance only for the time to progression, whereas residual tumor volume has for both time to progression and survival...
  27. ncbi Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer
    E Ioachim
    Department of Pathology, Medical School, University of Ioannina, Greece
    Breast 12:111-9. 2003
    ....
  28. ncbi Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study
    E Briasoulis
    Dept of Medical Oncology, School of Medicine, University of Ioannina, Greece
    J Exp Clin Cancer Res 20:341-4. 2001
    ....
  29. ncbi Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group
    A Bamias
    Oncology Department, Ioannina University Hospital, Ioannina, Greece
    Oncology 64:102-10. 2003
    ..We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin <10 g/dl) in patients with solid tumors receiving platinum-based chemotherapy...
  30. ncbi The diagnostic and therapeutic management of leptomeningeal carcinomatosis
    N Pavlidis
    School of Medicine, University of Ioannina, Greece
    Ann Oncol 15:iv285-91. 2004
  31. ncbi Metastatic involvement of placenta and foetus in pregnant women with cancer
    N Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, Greece
    Recent Results Cancer Res 178:183-94. 2008
  32. ncbi Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy
    E Briasoulis
    Department of Medical Oncology, University of Ioannina, Ioannina, 45110, Greece
    Oncologist 6:153-61. 2001
    ....
  33. ncbi The missing kiss of life: transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer
    L Kostadima
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Anticancer Res 27:2499-504. 2007
    ..KiSS-1 is a metastasis suppressor gene encoding a neuropeptide with potent antimetastatic activities in tumour cell lines. The transcriptional activity of the gene and its associations in resected breast cancer were analysed...
  34. ncbi Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature
    N Pavlidis
    Department of Medicine, School of Medicine, University of Ioannina, Greece
    J Chemother 6:417-22. 1994
    ..The combination is very well tolerated with minimal toxicity. A detailed review of the literature regarding the effectiveness of the above regimens on response rate, overall survival and toxicity is also presented...
  35. ncbi Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit
    L Dova
    Hematological Laboratory, Molecular Biology Unit, Ioannina University Hospital, Ioannina, Greece
    J Cancer Res Clin Oncol 134:697-704. 2008
    ....
  36. ncbi Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study
    E Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Anticancer Drugs 15:747-52. 2004
    ..The low hematological toxicity and modest activity observed leave questions concerning the optimal timing of this combination...
  37. ncbi Juvenile cancer: improving care for adolescents and young adults within the frame of medical oncology
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Dourouti 45110, Greece
    Ann Oncol 16:181-8. 2005
    ..Similar to geriatric and paediatric oncology, we call for the intensification of treatment, support and research multidisciplinary efforts in order to better fulfil the pressing demands of this patient group...
  38. ncbi ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)
    E Briasoulis
    Ioannina University Hospital, Dept. of Medical Oncology, 45110, Ioannina, Greece
    Ann Oncol 16:i75-6. 2005
  39. ncbi Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up
    E Briasoulis
    Department of Medical Oncology, University of Ioannina, Ioannina Ipiros, Greece
    Ann Oncol 19:ii106-7. 2008
  40. ncbi Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up
    G Pentheroudakis
    Department of Medical Oncology, Ioannina, Greece
    Ann Oncol 19:ii108-9. 2008
  41. ncbi Heterogeneity in cancer guidelines: should we eradicate or tolerate?
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Ann Oncol 19:2067-78. 2008
    ..Heterogeneity in aspects of development, structure and context of oncology guidelines was not evaluated. We analysed and critically examined its implications...
  42. ncbi Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature
    E Voulgaris
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, Ioannina 45500, Greece
    Lung Cancer 64:247-9. 2009
    ..Because of this fact clinicians should be alert to the occurrence of such clotting disorders and should be familiar with their diagnosis and management...
  43. ncbi The masterclass of the european school of oncology: the 'key educational event' of the school
    N Pavlidis
    Department of Medical Oncology, Medical School, University of Ioannina, Greece
    Eur J Cancer 46:2159-65. 2010
    ..In this paper, we are presenting data derived from the analysis of the questionnaire distributed to all participants...
  44. ncbi A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Neoplasma 57:47-54. 2010
    ..Keywords: KiSS1, metastasis-suppressor gene, breast cancer, mutation, transcription...
  45. ncbi Systemic dissemination in cancer of unknown primary is independent of mutational inactivation of the KiSS-1 metastasis-suppressor gene
    L Dova
    Molecular Biology Unit, Hematological Laboratory, Ioannina University Hospital, Ioannina, Greece
    Pathol Oncol Res 14:239-41. 2008
    ..Consequently, the propensity for systemic spread of unknown primary tumors may by due to mutations in genes other than KiSS1 or aberrant epigenetic regulation...
  46. ncbi Towards a convenient way to practice medical oncology
    N Pavlidis
    University of Ioannina, Greece
    Ann Oncol 18:ii3-4. 2007
  47. ncbi Cancer of unknown primary: biological and clinical characteristics
    N Pavlidis
    University of Ioannina Hospital, Department of Medical Oncology, Ioannina, Greece
    Ann Oncol 14:iii11-8. 2003
  48. ncbi Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time
    J P A Ioannidis
    Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, 45110, Ioannina, Greece
    Eur J Cancer 39:2278-87. 2003
    ..The proportion of enrolled patients with a performance status of 2 or worse decreased significantly over time (12.9% per decade, P<0.001). Randomised evidence in this field is fragmented and subject to considerable selection biases...
  49. ncbi Clear cell ovarian carcinoma in a pregnant woman with a history of infertility, endometriosis and unsuccessful IVF treatment
    G Makrydimas
    Department of Obstetrics and Gynecology, University Hospital of Ioannina, Ioannina, Greece
    Eur J Gynaecol Oncol 24:438-41. 2003
    ..Four months later the woman and baby are doing well. We review cases of ovarian clear cell carcinoma diagnosed during pregnancy and discuss the association of endometriosis, infertility, infertility drugs and ovarian cancer...
  50. ncbi Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features
    G Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Panepistimiou Avenue, 45110 Ioannina, Greece
    Lung Cancer 45:349-55. 2004
    ....
  51. ncbi SESy-Europe: a multi-language database dedicated to cancer screening monitoring
    D Mauri
    PACMeR Section of Public Health, Hospital and Health Centers, Ioannina, Greece
    J Exp Clin Cancer Res 23:441-5. 2004
    ..Due to its multi-language standardized characteristics its application may bridge European countries in cancer screening monitoring policy...
  52. ncbi The treatment of cancer in Greek antiquity
    A Karpozilos
    Department of Philology, School of Philosophy, University of Ioannina, Greece
    Eur J Cancer 40:2033-40. 2004
    ..460-370 B.C.) and the voluminous works of Galen (129-199 A.D.) and extends to medical handbooks (Oreibasios, Aetios of Amida, Paul of Aegina) composed in subsequent centuries up to the end of the ancient world (VII c. A.D.)...
  53. ncbi Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
    E Briasoulis
    Medical Oncology Department, University Hospital, Ioannina, Greece
    Cancer Chemother Pharmacol 56:521-8. 2005
    ..The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan...
  54. ncbi Rectal metastases from lobular carcinoma of the breast: report of a case and literature review
    A Bamias
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Ann Oncol 12:715-8. 2001
    ..Literature review revealed only a few more cases of metastatic breast carcinoma to the rectum. Awareness of this condition may lead to accurate diagnosis and early initiation of systemic treatment, thus avoiding surgical intervention...
  55. ncbi Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma
    Aristotle T Bamias
    Oncology Department, Ioannina University Hospital, Ioannina 451 10, Greece
    Cancer Invest 21:333-40. 2003
    ..Our results support previous data associating the DCC gene with differentiation and indicate that this gene may play a role in the metastatic potential of these tumors. These findings need to be confirmed by future larger studies...